These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20964610)

  • 1. Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.
    Neagu M; Constantin C; Tanase C
    Expert Rev Mol Diagn; 2010 Oct; 10(7):897-919. PubMed ID: 20964610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.
    Atreya I; Neurath MF
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):561-72. PubMed ID: 18402523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Function and prognostic significance of immune cells infiltrating human tumors].
    Ladányi A
    Magy Onkol; 2004; 48(1):49-56. PubMed ID: 15105896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
    Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
    Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immune system--a hidden treasure for biomarker discovery in cutaneous melanoma.
    Neagu M
    Adv Clin Chem; 2012; 58():89-140. PubMed ID: 22950344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
    Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
    Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in biomarkers for melanoma.
    Griewank KG; Ugurel S; Schadendorf D; Paschen A
    Curr Opin Oncol; 2013 Mar; 25(2):145-51. PubMed ID: 23334230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Old and new serological biomarkers in melanoma: where we are in 2009.
    Mouawad R; Spano JP; Khayat D
    Melanoma Res; 2010 Apr; 20(2):67-76. PubMed ID: 20093989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
    Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
    Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update of diagnostic and prognostic markers in cutaneous malignant melanoma.
    Reed JA; Albino AP
    Clin Lab Med; 2000 Dec; 20(4):817-38. PubMed ID: 11221516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immuno-diagnosis of malignant melanoma].
    Szekeres G; Battyáni Z
    Magy Onkol; 2003; 47(1):45-50. PubMed ID: 12704454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
    Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
    Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common skin cancers.
    Lee PK
    Minn Med; 2004 Mar; 87(3):44-7. PubMed ID: 15080294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with melanoma incidence and prognosis.
    Lee JE
    Semin Surg Oncol; 1996; 12(6):379-85. PubMed ID: 8914201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.
    Ladányi A
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):490-500. PubMed ID: 25818762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Laboratory markers of melanoma progression].
    Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
    Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.